Silymarin, a gold standard drug used to treat hepatic disorder is an extract obtained from the seed of the Milk thistle (Silybum marianum) belonging to the family of Asteraceae. Silybin A, silybin B, silychristin A, silychristin B, isosilybin A, isosilybin B, and silydianin are the major component associated with it. A C25 containing flavonoid, a potent antioxidant i.e. silymarin used to treat the cerebral ischemic haemorrage, and protective against cognitive deficits, brain damage and other CNS disorders. It is reported to have anticonvulsant, antidepressive, anticancer, anti-inflammation, antidiarrheal, antiulcer and vasodilator properties. It prevents conversion of Dopamine (DA) to DOPAC by inhibiting the dopamine oxidizing enzyme and monoamine Oxidase-B hence, leads to lesser degradation of DA and increased extracellular concentration of catecholamine neurotransmitter. Silymarin also inhibit the activation of NF-Kβ, P38MAPK to prevent inflammatory response, protect formation of Aβ oligomerization with fibrilization to prevent oxidative stress and neuronal inflammation. Silymarin inhibit the activation of glycogen synthase kinase 3-β, production of P58, Apaf-α and caspase activation. It increases expression of BDNF which is essential for formation of neuronal synaptic connection for growth and learning. Hence, this presentation will focus on its clinical importance in a variety of neurodegenerative disorders and also offer improvements in its bioavailability to accurately validate its neuroprotective efficacy.
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